- Have you or a loved one been diagnosed with Alzheimer's Disease?
- See if you qualify to join the Kioku Study.
Study Summary
What is the study drug?
The study drug is an oral drug that is being tested as a possible treatment for Alzheimer's disease. The study drug, called T-817MA, is different from other Alzheimer's disease drugs including those currently in clinical testing. Pre-clinical research has shown that the study drug protected brain cells, stimulated the re-growth of damaged brain cells and prevented memory loss.
T-817MA has been studied in over 100 healthy people including elderly volunteers. This included some elderly patients who received the drug every day for six weeks at the dose now being given in this study.
What are volunteers asked to do during the Kioku Study?
Qualified study participants will be asked to participate in the study for approximately 1 year.
Patients and their primary caregivers will have 9 visits from the initial screening through a follow-up visit. During these visits, the patient's safety will be assessed and the caregiver will be interviewed. Additionally, the patient's Alzheimer's disease will be assessed by an evaluator.
Patients will receive study-related routine medical care and physical exams throughout the study. Patients will have electrocardiogram procedures performed at each visit. There will also be routine blood draws and urine samples taken for laboratory tests.
Patients will take 2 tablets once daily. Half of the patients will receive study drug and the other half will receive placebo (sugar pill). All patients will continue to take their prescribed Aricept throughout the study.
Provided at no cost to qualified study participants:
- All study-related medical exams
- Memory tests
- Physical exams and laboratory tests
- Study drug